Our companies

Empowering change through science

We are full life cycle investors supporting scientists and entrepreneurs at any stage where we identify opportunity, from academic programs in need of industry sponsorship all the way to mature publicly traded companies.

Ancora Heart

A medical device company dedicated to providing new treatment options for people with heart failure (HF). The company’s proprietary AccuCinch® Ventricular Restoration System is the first completely percutaneous device designed to restore the enlarged left ventricle of the heart, thereby addressing the fundamental issue in the progression of systolic heart failure.

Disease/TX area
Cardiovascular
Avidity Biosciences

We are delivering a new class of RNA therapeutics - AOCs - which combine the specificity of monoclonal antibodies and the precision of oligonucleotides. Through integrating these proven technologies, our AOC platform is able to deliver to previously inaccessible tissue and cell types and more effectively target the underlying genetic drivers of diseases. With an agile and diverse team, we are advancing and expanding our pipeline programs to offer treatment options for patients and their families.

Disease/TX area
Myotonic Dystrophy
Beta Bionics

The developer of the iLet®, a revolutionary bionic pancreas driven by machine-learning artificial intelligence to autonomously control blood sugar.

Disease/TX area
Type 1 Diabetes
CinCor Pharma

A clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, baxdrostat (CIN-107), for the treatment of hypertension and other cardio-renal diseases. It is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland.

Disease/TX area
Cardiovascular
CORXEL

CORXEL is a leading biotechnology company committed to bringing innovative cardiometabolic medicines to underserved patients around the world.

Disease/TX area
Cardiometabolic
Founded
2019
Encoded

Developing life-changing therapeutics for severe genetic disorders that are not addressable with existing gene therapy approaches.

GH Research

A clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Disease/TX area
Neurology
Milestone Pharmaceuticals Inc

A late-stage biopharmaceutical company developing a drug intended to provide outpatient treatment of paroxysmal supraventricular tachycardia (PSVT).

Disease/TX area
Cardiovascular
NiKang

A preclinical stage biotech company discovering and developing innovative small molecule oncology medicines.

Disease/TX area
Oncology
Orchestra BioMed

The developer of Virtue SEB, a sirolimus eluting balloon for treatment of coronary and peripheral arterial disease.

Disease/TX area
Cardiovascular
Prometheus Biosciences Inc

Discovering and developing novel therapeutic and companion diagnostic products for the diagnosis and treatment of inflammatory bowel disease (IBD).

Disease/TX area
IBD
Rocket Pharmaceuticals Inc

Bringing hope and relief to patients with undertreated rare diseases through the development and commercialization of curative first-in-class gene-modified cell therapies.

Disease/TX area
Rare pediatric diseases
Founded
2015
Tarsus

Focused on the development and commercialization of first-in-class therapeutic candidates to address large market opportunities initially in ophthalmic conditions such as Demodex blepharitis.

Disease/TX area
Ophthalmology
Ventyx

Advancing a pipeline of novel small molecule therapeutics with a best-in-class potential for patients with inflammatory and autoimmune diseases.

Disease/TX area
Inflammatory, Autoimmune
Visus

A clinical-stage pharmaceutical company developing presbyopia-correcting eye drop.

Disease/TX area
Ophthalmology

Rod dug in our company when many other investors disappeared. He did the work and realized BioCryst’s potential for treating rare diseases such as HAE long before others did.

Jon Stonehouse
Jon Stonehouse
CEO, BioCryst

The RTW Team spotted the argenx investment opportunity ahead of the curve and rapidly developed from an investor to a loyal partner. Their data based approach and desire to understand resonates very well with our company culture.

Tim Van Hauwermeiren
Tim Van Hauwermeiren
CEO, Argenx

We view the team at RTW with highest regard. They believed in Alnylam's potential when the rest of the world was skeptical.

John Maraganore, PhD
John Maraganore, PhD
Founding CEO, Alnylam Pharmaceuticals

RTW uses scientific and clinical acumen to decipher critical investments. Rod and Piratip were excellent strategic partners who had the foresight to invest in Avexis.

Sukumar Nagendran, MD
Sukumar Nagendran, MD
Chief Medical Officer, Avexis

Rod and the team at RTW dug deep into our science, saw our potential early and share our drive to bring science to patients. As a member of our board, Rod’s wisdom and guidance has been invaluable. RTW is more than an investor, they are a true partner.

Sarah Boyce
President and CEO, Avidity

RTW is a very insightful and strategic investment firm. They had the foresight to invest in PTC after our acquisition of Emflaza and have spent a significant amount of time and effort to understand the potential of our pipeline.

Stu Peltz
Stu Peltz
CEO, PTC Therapeutics

RTW is among the most thoughtful and diligent teams we have encountered. They saw the commercial potential of MACI early on, and have been a tremendous partner to Vericel during a period of rapid growth for the company.

Nick Colangelo
Nick Colangelo
CEO, Vericel

RTW really took the time to understand our business, and they understood that the reasons that other people had said no were actually the very reasons to say yes. They backed us early and made good on their promise to be a true partner long after Establishment Labs' IPO. They are the entrepreneur's investor and a real value add.

Nick Lewin
Nick Lewin
Chairman, Establishment Labs

RTW’s passion for science and rational approach toward therapeutics development have been essential to the RCKT story. Rod and team have an uncanny ability to identify opportunities that no one else has, well ahead of the curve, and the rigorous discipline to water them gently. We value them highly as top shareholders, as founders and integral members of the Board, and most importantly as friends.

Gaurav Shah, MD
Gaurav Shah, MD
CEO, Rocket Pharmaceuticals

The RTW team did deep commercial diligence into the potential for a prophylactic HAE medicine well before other investors. Combined with their deep understanding of science, RTW was a terrific long-term shareholder, as we advanced DX-2930 through the clinic and sought to bring this important therapy to patients.

George Migausky
George Migausky
CFO, Dyax

The investments listed above include RTW funds’ investments in private companies that have had a liquidity event, or are investments of RTW Biotech Opportunities, Ltd. They do not include names of investments for which RTW is under non-disclosure obligations or in certain circumstances that are related to the protection of RTW’s competitive edge.

The discussion is included for informational purposes only and is intended to be illustrative but is not representative of transactions of a given type in which RTW may invest on behalf of the Funds. There can be no assurance that the Funds will achieve comparable results.

The above testimonials were given by CEOs or other senior executives of companies in which RTW has made an equity investment on behalf of managed funds. No compensation was provided to the individuals giving the testimonials. Guarav Shah is also an investor in RTW managed funds. Stu Peltz is also a director of the board of Health Sciences Acquisitions Corporation 2, a SPAC sponsored by RTW Investments, LP, for which he has received stock grants in exchange for his service as a director. Since January 2022 John Maraganore has been an advisor to RTW Investments, LP, serving as Executive Partner.

This website is not intended to offer or to promote the offer or sale of the shares (the “Shares”) of RTW Biotech Opportunities Ltd (the “Company”) in the United States or to any “U.S. persons” as defined in Regulation S (“US persons”) under the US Securities Act of 1933, as amended (the “Securities Act”). The materials contained herein are not for release, publication or distribution, directly or indirectly, in whole or in part, to any persons to whom or into or within any jurisdiction where to do so would constitute a violation of applicable law or regulation.

The information contained herein and on the pages that follow does not constitute or form a part of any offer to sell or issue, or the solicitation of any offer to purchase, subscribe for or otherwise acquire, any securities in the United States or in any jurisdiction in which, or to any person to whom, such an offer or solicitation would be unlawful.

The Company has not been and will not be registered under the US Investment Company Act of 1940, as amended (the “Investment Company Act”), and as such holders of the Shares are not and will not be entitled to the benefits of the Investment Company Act. The Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, delivered, assigned or otherwise transferred, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not result in the Company being required to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. The offer and sale of the Shares have not been and will not be registered under the applicable securities laws of Australia, Canada, Japan or South Africa. Potential users of the information contained herein and on the pages that follow are requested to inform themselves about and to observe all applicable restrictions.

The information contained herein and on the pages that follow may contain forward-looking statements. Any statement other than a statement of historical fact is a forward-looking statement. Actual results may differ materially from those expressed or implied by any forward-looking statement. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. You should not place undue reliance on any forward-looking statement, which speaks only as of the date of its issuance. The Company may change these terms and conditions from time to time and any such changes will be posted on this website. Your access to this website is governed by the version of these terms and conditions then in force.

By clicking “Agree” below, you represent, warrant, undertake and agree that (1) you have read, understood and agree to be bound by the terms and conditions and other information set out herein, (2) you are permitted under applicable laws and regulations to receive the information contained herein and on the pages that follow, (3) you are either (a) located outside the United States and are not a US Person or (b) an existing shareholder of the Company who is a “qualified purchaser” as defined under the Investment Company Act and (4) you will not further transmit or send any information contained in this website to any other persons in the United States, to US Persons, or to any publications with a general circulation in the United States. If you cannot so represent, warrant, undertake and agree, you must click the button labelled “Decline” or otherwise exit this website.